Can Hidradenitis Suppurativa Go Away for Good? What the Long-Term Evidence Shows

Hidradenitis suppurativa (HS) cannot go away for good in the strict sense of a permanent cure, but roughly 40 to 60 percent of people with mild disease reach long stretches of remission, and up to 30 percent of early-stage cases improve substantially without treatment escalation. HS is a chronic, relapsing inflammatory condition of the hair follicle, so the biological tendency persists even when symptoms vanish. Modern biologics, notably adalimumab and secukinumab, push about 40 to 50 percent of moderate-to-severe patients to at least 50 percent clinical improvement. The realistic goal is durable control, not eradication.

The Mechanism: Why HS Keeps Coming Back

HS is not an infection and not a hygiene problem. It begins when keratin plugs the follicular infundibulum, the upper funnel of a hair follicle. The plugged follicle dilates and ruptures, spilling keratin, bacteria, and cellular debris into the surrounding dermis. The immune system reacts with a neutrophil-heavy inflammatory cascade, and repeated cycles of this process remodel the tissue into sinus tracts, scars, and fibrotic cords.

The relapsing nature comes from two layers. First, the follicular abnormality that triggers plugging is structural and genetic, so new follicles keep entering the cycle. Second, the inflammatory memory sits in the tissue. Once sinus tracts form, they become reservoirs that shed debris and flare under triggers such as friction, hormonal shifts, and smoking. In plain terms: the fire can be put out, but the fuel source stays in the skin.

The follicular occlusion is the primary event, and infection is secondary. This is why antibiotics help partly through anti-inflammatory action rather than purely by killing bacteria. It also explains why surgical removal of affected tissue can produce long-term clearance in a way that drugs alone rarely do.

Quantified Context: How Often Does HS Actually Resolve?

Studies tracking HS over years give a more sober picture than internet anecdotes suggest. Disease activity fluctuates, and complete sustained remission without any treatment is uncommon in moderate-to-severe disease.

These ranges come from longitudinal cohort observations; exact figures vary by population and follow-up length. The pattern is consistent: the earlier the stage, the better the odds of quiet periods. Once sinus tracts and scarring dominate, the disease rarely disappears on its own.

Biologic response rates sharpen the picture. In pivotal trials, adalimumab achieved a Hidradenitis Suppurativa Clinical Response (HiSCR, a 50 percent reduction in abscess and nodule count) in about 42 to 50 percent of patients at week 12. Secukinumab reached similar HiSCR rates, near 45 percent, in its phase 3 program per the 2024 published trials. HiSCR is meaningful improvement, not remission, and response can wane over months.

Variations and Edge Cases: Who Improves and Who Does Not

HS behaves differently across subgroups, and this shapes whether "going away" is realistic.

Early-stage, self-limited disease. Some adolescents and young adults with mild, localized HS see it quiet down in their late twenties. Hormonal stabilization and weight change are plausible contributors, though this is observation rather than proven causation.

Postmenopausal women. Flares often decrease after menopause as androgen and estrogen patterns shift. The 2017 and later dermatology consensus notes this pattern but does not promise resolution.

Tobacco users. Smoking is associated with more severe disease and a lower chance of remission. Quitting correlates with improvement in some cohorts, but the evidence is associative.

Weight and metabolic status. Obesity and insulin resistance correlate with severity. Bariatric surgery has produced dramatic HS improvement in case series, which points to a metabolic driver, though this remains an area of active hypothesis rather than settled mechanism.

Surgical intervention. Wide local excision of affected skin can clear disease in that anatomic region permanently, because the follicles are gone. Recurrence happens at wound margins or in new areas, not in the excised bed. This is the closest thing to a durable local cure.

Correcting Misconceptions

A few ideas circulate widely and mislead people.

Misconception one: HS is caused by poor hygiene or is contagious. Neither is true. The follicular occlusion is internal, and HS does not spread to others.

Misconception two: a remission means the disease is "cured." Remission is a quiet period, and the underlying tendency can reactivate years later. People who stop treatment abruptly during remission often flare.

Misconception three: antibiotics will fix it permanently. Long courses of doxycycline or clindamycin-rifampin help control flares, but they suppress rather than eliminate the follicular cycle.

Misconception four: surgery is a last resort. For localized, tract-heavy disease, early excision can prevent spread and produce lasting clearance, so timing matters more than sequence.

The counterintuitive point: HS often looks worse than it feels, and feels worse than it looks. Pain and drainage drive quality of life more than visible extent in many patients, so clinical scores and patient experience can diverge.

Practical Actions: What to Actually Do

Concrete steps improve the odds of long, quiet periods.

• Stop smoking. This is the single most modifiable risk factor for severity.
• Reach and hold a healthy weight if overweight. Even modest loss correlates with fewer flares in observational data.
• Use gentle skin care and avoid tight synthetic clothing over affected areas. Friction triggers flares.
• Track flares with photos and a simple log of location, pain, and duration. This guides treatment timing.
• Discuss biologic therapy early if you have moderate-to-severe disease with tracts. Delaying escalation allows more scarring.
• Ask about surgical referral for localized, recurrent, tract-forming lesions. Early excision beats late.

Red-flag warning signs that need urgent medical review:

• Rapidly spreading redness, fever, or systemic symptoms suggesting a secondary infection.
• New severe pain with swelling in a sinus tract that may signal an abscess needing drainage.
• Sudden worsening after starting a new medication.
• Signs of anemia or weight loss with chronic drainage.

Timeline: What Remission and Relapse Look Like

The time course matters because expectations shape decisions.

Comparing Treatment Paths and Their Durability

Limitations and What Remains Uncertain

The honest caveat is that HS research is younger than research on psoriasis or rheumatoid arthritis. Many remission percentages come from cohorts rather than randomized trials, so the numbers carry uncertainty. We do not yet have a validated biomarker that predicts who will stay in remission. Genetic studies point to variants near the gamma-secretase genes in familial cases, but most HS is not familial, and the trigger for sporadic disease is not fully mapped.

Treatment durability data beyond five years are sparse. Biologic registries are growing, and long-term safety and persistence figures will improve. Until then, the realistic statement is this: HS can go quiet for years, sometimes for a decade or more, and localized disease can be removed permanently by surgery, but the underlying tendency rarely disappears. Durable control is achievable. Permanent eradication is not yet.